PD-1用多久,能不能停药?PD-L1与PD-1有何不同?一文读懂!
2023-05-18 e药安全 网络
PD-1用多久,能不能停药?PD-L1与PD-1有何不同?一文读懂!
![01.png](https://img.medsci.cn/images/20230425/7b28114991c1452bb7000cb946200e68.jpg)
![02.jpg](https://img.medsci.cn/images/20230425/d43186efb8444bbeac624e0572cde61f.jpg)
![01.png](https://img.medsci.cn/images/20230425/8b4c82006dc7484dbc02685d67fcb9cd.jpg)
![04.png](https://img.medsci.cn/images/20230425/9a4d2ac63dd84701bdb99a8a84beb5f3.jpg)
![](https://img.medsci.cn/images/20230425/3af68f54735746ceaba3ad93a318d32c.jpg)
![06.png](https://img.medsci.cn/images/20230425/614ff835591d4503ac36052db631c480.jpg)
![](https://img.medsci.cn/images/20230425/c9e973a52596465abfcab7d2da1d46de.jpg)
![](https://img.medsci.cn/images/20230425/1ca1c5ebd05b45c5b08ad0055ac926cd.jpg)
目前,国内共有16种PD-1/PD-L1等肿瘤免疫检查点抑制剂获批上市,适应症涵盖多种恶性肿瘤,大幅提升了患者的生存期。
具体适应症详见如下(建议收藏):
![](https://img.medsci.cn/images/20230425/7dc77de797a343088e172bb10bd529ee.jpg)
参考文献:
[1].Drew M. Pardoll. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer. 2012 Mar 22;12(4):252-64.
[2].Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[J]. Sci Rep. 2019 Aug 7;9(1):11472.
[3].Jifeng Yu, Yongping Song, Wenzhi Tian. How to select IgG subclasses in developing anti-tumor therapeutic antibodies[J]. J Hematol Oncol. 2020 May 5;13(1):45.
[4].Kim C Ohaegbulam, Amer Assal, Eszter Lazar-Molnar, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J]. Trends Mol Med. 2015 Jan;21(1):24-33.
[5].Maud Mayoux, Andreas Roller, Vesna Pulko, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy[J]. Sci Transl Med. 2020 Mar 11;12(534):eaav7431.
推荐阅读
肺癌系列文章汇总
肺癌相关指南及专家共识大汇总
微信扫一扫
关注该公众号
使用小程序
作者:e药安全
版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言